+34 620 10 75 37info@nanbiosis.com

Posts Taged gene-therapy

You are here : Home / Posts Tagged "Gene therapy"

Three articles acknoledging NANBIOSIS contribution awarded at the Bioaraba Research and Innovation Conference

Researchers of NANBIOSIS U10 “Drug Formulation” – NanoBiocel research group from CIBER-BBN and UPV/EHU receives 3 awards in the category of Best International Articles at the annual Bioaraba Research and Innovation Conference.

On 4 November, the Bioaraba Health Research Institute held its XXIII Research and Innovation Conference in Vitoria. This important annual forum held in the city brings together professionals from the health system of Alava, the Rioja region of Alava, the Mental Health Network of Alava, the University of the Basque Country and also professionals from companies in R&D&I in health.

On this occasion, the NanoBioCel research group of the CIBER BBN and the ICTS Nanbiosis through the U10 Drug Formulation, won the 3 prizes in the category of Research and Innovation in the category of Best International Article. The first prize went to the article: Mesenchymal stromal cells encapsulated in licensing hydrogels exert delocalized systemic protection against ulcerative colitis via subcutaneous xenotransplantation. Written by Ainhoa Gonzalez-Pujana, Ana Beloqui, José Javier Aguirre, Manoli Igartua, Edorta Santos-Vizcaino, Rosa Maria Hernandez, published in the European Journal of Pharmaceutics and Biopharmaceutics in 2022. The second prize went to the article Nanodiamond Integration into Niosomes as an Emerging and Efficient Gene Therapy Nanoplatform for Central Nervous System Diseases whose authors are: Nuseibah AL Qtaish, Idoia Gallego, Alejandro J. Paredes,Ilia Villate, Cristina Soto-Sánchez, Gema Martínez, Myriam Sainz-Ramos, Tania B. López, Eduardo Fernández, Gustavo Puras, José Luis Pedraz. And the third prize went to the review: Cell microencapsulation technologies for sustained drug delivery: Latest advancesin efficacy and biosafety whose authors are: Tania B. López, Edorta Santos, José Luis Pedraz, Gorka Orive, Rosa María Hernández.

Articles of refernce:

Ainhoa Gonzalez-Pujana, Ana Beloqui, José Javier Aguirre, Manoli Igartua, Edorta Santos-Vizcaino, Rosa Maria Hernandez, “Mesenchymal stromal cells encapsulated in licensing hydrogels exert delocalized systemic protection against ulcerative colitis via subcutaneous xenotransplantation“, European Journal of Pharmaceutics and Biopharmaceutics, Volume 172,
2022, https://doi.org/10.1016/j.ejpb.2022.01.007

Nuseibah AL Qtaish, Idoia Gallego, Alejandro J. Paredes, Ilia Villate-Beitia, Cristina Soto-Sánchez, Gema Martínez-Navarrete, Myriam Sainz-Ramos, Tania B. Lopez-Mendez, Eduardo Fernández, Gustavo Puras, José Luis Pedraz. “Nanodiamond Integration into Niosomes as an Emerging and Efficient Gene Therapy Nanoplatform for Central Nervous System Diseases” ACS Appl. Mater. Interfaces 2022, 14, 11, 13665–13677 https://doi.org/10.1021/acsami.2c02182

Tania B. Lopez-Mendez, Edorta Santos-Vizcaino, Jose Luis Pedraz, Gorka Orive, Rosa Maria Hernandez, “Cell microencapsulation technologies for sustained drug delivery: Latest advances in efficacy and biosafety,
Journal of Controlled Release”, Journal of Controlled Release, Volume 335, 10 July 2021, Pages 619-636 https://doi.org/10.1016/j.jconrel.2021.06.006


• Read More

OPEN SUBMISSION FOR JOURNAL SPECIAL ISSUE ON OLIGONUCLEOTIDE BASED THERAPIES

Dr. Ramon Eritja, Scientific Director of NANBIOSIS unit 29 of Oligonucleotide Synthesis Platform (OSP) and Dr. Santiago Grijalvo researcher at NANBIOSIS unit 12 of Nanostructured liquid characterization, from CIBER-BBN and IQAC-CSIC, together with Dr. Andreia F. Jorge, from Coimbra Chemistry Centre (CQC), acting as guest editors of journal Pharmaceutics, of MDPI Publisher, welcome authors to submit their articles on special issues on Recent Trends in Oligonucleotide Based Therapies.

In the past few decades, significant efforts have been made towards the clinical application of oligonucleotides. However, the potential of the therapeutic applications of RNA-based strategies have recently been spotlighted after the first approval of mRNA vaccines in response to COVID-19 pandemic. These molecules have the power to tackle targets that are usually considered to be “undruggable” by blocking the translation or transcription of a specific gene by stimulating the degradation of a particular messenger RNA.

This Special Issue aims to collect reviews, original research articles, and short communications covering innovative strategies in the design, synthesis, and characterization of therapeutic oligonucleotides as well as advances in their delivery based on nanotechnologies. Research concerning the study of sequence-specific protein–DNA/RNA interactions will be also considered.

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form.

For all the informations and instructions about the Special Issue, please visit this MDPI page

Deadline for submissions: 31 December 2022

• Read More

Non-viral mediated gene therapy in human cystic fibrosis airway epithelial cells recovers chloride channel functionality

Researchers of CIBER-BBN Units of NANBIOSIS: U29 Oligonucleotide Synthesis Platform (OSP) at IQAC_CSIC, led by Prof. Ramón Eritja and U10 Drug Formulation, at UPV-EHU, led by Prof José Luis Pedraz, are coauthors of an article published by International Journal of Pharmaceutics.

Gene therapy strategies based on non-viral vectors are currently considered as a promising therapeutic option for the treatment of cystic fibrosis (CF), being liposomes the most commonly used gene carriers. Niosomes offer a powerful alternative to liposomes due to their higher stability and lower cytotoxicity, provided by their non-ionic surfactant and helper components. In this work, a three-formulation screening is performed, in terms of physicochemical and biological behavior, in CF patient derived airway epithelial cells. The most efficient niosome formulation reaches 28% of EGFP expressing live cells and follows caveolae-mediated endocytosis. Transfection with therapeutic cystic fibrosis transmembrane conductance regulator (CFTR) gene results in 5-fold increase of CFTR protein expression in transfected versus non-transfected cells, which leads to 1.5-fold increment of the chloride channel functionality. These findings highlight the relevance of niosome-based systems as an encouraging non-viral gene therapy platform with potential therapeutic benefits for CF.

The article acknowledges U10 Drug Formulation, for the intellectual and technical assistance

Article or reference:

Non-viral mediated gene therapy in human cystic fibrosis airway epithelial cells recovers chloride channel functionality-Sainz-Ramos, M., Villate-Beitia, I., Gallego, I., A.L. Qtaish, N., Lopez-Mendez, T.B., Eritja, R., Grijalvo, S., Puras, G., Pedraz, J.L. International Journal of Pharmaceutics, 588, art. no. 119757, 2020. https://doi.org/10.1016/j.ijpharm.2020.119757

• Read More

Switching cell penetrating and CXCR4-binding activities of nanoscale-organized arginine-rich peptides

Scientists of Units 1 and 18 of NANBIOSIS are coathors of the article  “Switching cell penetrating and CXCR4-binding activities of nanoscale-organized arginine-rich peptides” published by Nanomedicine: Nanotechnology, Biology and Medicine

Arginine-rich protein motifs have been described as potent cell-penetrating peptides (CPPs) but also as rather specific ligands of the cell surface chemokine receptor CXCR4, involved in the infection by the human immunodeficiency virus (HIV).

Polyarginines are commonly used to functionalize nanoscale vehicles for gene therapy and drug delivery, aimed to enhance cell penetrability of the therapeutic cargo. However, under which conditions these peptides do act as either unspecific or specific ligands is unknown. The authors have here explored the cell penetrability of differently charged polyarginines in two alternative presentations, namely as unassembled fusion proteins or assembled in multimeric protein nanoparticles. By this, they have observed that arginine-rich peptides switch between receptor-mediated and receptor-independent mechanisms of cell penetration. The relative weight of these activities is determined by the electrostatic charge of the construct and the oligomerizationstatus of the nanoscale material, both regulatable by conventional protein engineering approaches

Protein production has been partially performed by the ICTS “NANBIOSIS”, more specifically by the U1. Protein Production Platform (PPP), whereas the in vivo biodistribution assays were performed in the NANBIOSIS U18. Nanotoxicology Unit,

Article of reference:

Marianna Teixeira de Pinho Favaro, Naroa Serna, Laura Sánchez-García, Rafael Cubarsi, Mónica Roldán, Alejandro Sánchez-Chardi, Ugutz Unzueta, Ramón Mangues, Neus Ferrer-Miralles, Adriano Rodrigues Azzoni, Esther Vázquez, Antonio Villaverde. Switching cell penetrating and CXCR4-binding activities of nanoscale-organized arginine-rich peptides Nanomedicine: Nanotechnology, Biology and Medicine Volume 14, Issue 6, August 2018, Pages 1777-1786 

 

 

• Read More

Nanotechnology, gene therapy, omics therapies and ‘big data’

Nanotechnology, gene therapy, omics therapies and ‘big data’ were the topics discussed in the Forum on Emerging Technologies oganized on May 8 by nanotechnology, gene therapy, omics therapies and ‘big data’ were the topics discussed in the I Forum on Emerging Technologies held on May 8, organized by the CIBER Internationalization Platform, of which the CIBERER, the CIBER-BBN and the CIBERES.

The objective of this event, structured in sessions of presentations and scientific debates about the types of technologies addressed, was to promote the exchange of ideas and scientific knowledge with the aim of generating new collaborations among the CIBER research groups  such as participation in transversal projects or the development of cutting-edge technologies.

NANBIOSIS was represented by Pablo Laguna (Unit 27, High Performance Computing), Laura Lechuga (Unit 4, Biodeposition and Biodetection Unit), José Luis Pedraz (Unit 10, Drug Formulation) and Rosa Villa (Unit8, Micro – Nano Technology Unit)

• Read More

I Forum on Emerging Technologies organized by CIBER

On May 8th, will take place in Madrid, at the Assembly Hall Ernest Lluch of the Instituto de Salud Carlos III, organized by CIBER Internationalization Platform (CIBER-BBN, CIBERER, CIBERES) the I Forum on Emerging Technologies.

The objective of this meeting is to promote the exchange of ideas and scientific knowledge among the CIBER research groups with the aim of generating new collaborations for participation in cross-cutting projects and the development of border technologies. The content of the forum, centered on the type of technology and possibilities it offers, is structured in a program of lectures and scientific debates whose final objective is the discussion and the joint generation of ideas. This first edition of the forum will be focused on Gene Therapy, Nanotechnologies and Omic Technologies-Big Data.

Some Units of NANBIOSIS will participate:

  • José Luis Pedraz, Scientific Director of  Unit 10 Drug Formulation, will speak of “Development of non-viral vectors for gene therapy“
  • Laura Lechuga, Scientific Director of Unit 4  Biodepositon and Biodetection, will talk about “Nanodispositive biosensors for advanced clinical diagnosis
  • Rosa Villa, Scientific Director of Unit 8 Micro–Nano Technology, Ramón Martínez, Scientific Director of Unit 26 NMR Biomedical Applications II and Esther Pueyo, researcher of U27 High Performance Computer will moderate the sessions.

 

Programme and registration details

 

• Read More

Nanotechnology and biomedical applications. Gene therapy

Yesterday, at the University of Zaragoza, Prof. Nuria Vilaboa (CIBER-BBN– Hospital Universitario de La Paz) gave a talk  on “Nanotechnology and biomedical applications. Gene therapy“.

The event was organized by Manuel Arruebo II Institute of Nanoscience of Aragon), researcher of the coordinating group of Unit 9 of NANBIOSIS.

In recent years, a multitude of materials of nanometric size have been explored, which because of their small size have properties that give them a great attraction for a wide range of biomedical applications. Prof. Vilaboa reviewed gene therapy technology, where materials at  nanoscale offer interesting alternatives.

• Read More